drugset / Trial / NCT07556640
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
Timeline
- Start
- 2026-04-17
- Primary completion
- 2028-04-30
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Paclitaxel | Small molecule | 20 mg/m2 | Other |
| Background | S-1 | Small molecule | 40 mg | Oral |
| Background | S-1 | Small molecule | 50 mg | Oral |
| Background | S-1 | Small molecule | 60 mg | Oral |
| Background | TPX4589 | Other / unclassified | 2 mg/kg | Intravenous |